Abstract
Both CD4+ and CD8+ CTL responses specific for the HIV-1 envelope proteins can be elicited in seronegative humans by candidate AIDS vaccines. The phenotype of the responding CTL depends upon the nature of the vaccine, with CD8+ CTL being found exclusively in recipients of live virus vaccines. Both types of CTL are active against HIV-1-infected cells in vitro. However, the potential efficacy of vaccine-induced CTL in preventing infection in vaccinated individuals exposed to HIV-1 is unknown and is likely to be dependent upon complex factors including lytic activity against divergent strains, cytokines produced, and the lysis of noninfected CD4+ T cells.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
AIDS Vaccines / immunology*
-
CD4-Positive T-Lymphocytes / immunology
-
Clone Cells / immunology
-
Gene Products, env / administration & dosage
-
Gene Products, env / immunology*
-
HIV Antigens / administration & dosage
-
HIV Antigens / immunology*
-
HIV Envelope Protein gp120 / immunology
-
HIV Envelope Protein gp160
-
HIV Seropositivity / immunology*
-
HIV-1 / immunology*
-
HLA-D Antigens / immunology
-
Humans
-
Immunity, Cellular
-
Lymphocyte Activation
-
Protein Precursors / immunology
-
T-Lymphocyte Subsets / immunology*
-
Vaccines, Attenuated / immunology
-
Vaccines, Synthetic / immunology*
Substances
-
AIDS Vaccines
-
Gene Products, env
-
HIV Antigens
-
HIV Envelope Protein gp120
-
HIV Envelope Protein gp160
-
HLA-D Antigens
-
Protein Precursors
-
Vaccines, Attenuated
-
Vaccines, Synthetic